Piper Jaffray analyst David Amsellem upgraded Endo to Overweight from Neutral with a price target of $7, up from $5. Feedback from his recent physician survey has raised his confidence that collagenase clostridium histolyticum in cellulite is "going to be a real contributor," said Amsellem, who believes Endo shares are not adequately reflecting the company's durable EBITDA stream. He is also increasingly confident based on checks with legal experts that opioid-related litigation settlement outcomes will "ultimately fall well short" of pushing Endo into a liquidity crisis, the analyst tells investors.